Association between IPTA Gene Polymorphisms and Hematological Abnormalities in Hepatitis C Virus-Infected Patients Receiving Combination Therapy

BACKGROUND/AIMS: Hematological abnormalities during hepatitis C virus (HCV) combination therapy with pegylated interferon α and ribavirin often necessitate dose reduction. Variants of the ITPA gene have been reported to protect against anemia during the early stages of HCV combination treatments but...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Jow-Jyh, Lo, Ching-Chu, Lin, Chien-Hung, Cheng, Hsu-Sheng, Hung, I-Wen, Tsai, Wan-Ju, Hung, Chien-Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Gut and Liver 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351029/
https://www.ncbi.nlm.nih.gov/pubmed/25287171
http://dx.doi.org/10.5009/gnl14095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351029/
https://www.ncbi.nlm.nih.gov/pubmed/25287171
http://dx.doi.org/10.5009/gnl14095

Ejemplares similares